-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, PlBywwyI3bRGvXOsJV8GDqnR5MZf8zMPPznhvNmQA0ChMA8D5sCtLgx2s/7eQImK 6XoluWbywAHZ7p3jrg2vVg== 0000898430-97-004738.txt : 19971111 0000898430-97-004738.hdr.sgml : 19971111 ACCESSION NUMBER: 0000898430-97-004738 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 3 FILED AS OF DATE: 19971110 SROS: NASD GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND L P ET AL GROUP MEMBERS: BIOTECHNOLOGY VALUE FUND, L.P. GROUP MEMBERS: BVF INC. SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: MICROCIDE PHARMACEUTICALS INC CENTRAL INDEX KEY: 0001010915 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943186021 STATE OF INCORPORATION: CA FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: SEC FILE NUMBER: 005-47911 FILM NUMBER: 97712039 BUSINESS ADDRESS: STREET 1: 850 MAUDE AVE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 4154281550 MAIL ADDRESS: STREET 1: 850 MAUDE AVE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BIOTECHNOLOGY VALUE FUND L P ET AL CENTRAL INDEX KEY: 0000918923 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 363924731 STATE OF INCORPORATION: DE FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-288-2395 MAIL ADDRESS: STREET 1: ONE SANSOME STREET STREET 2: 39TH FLOOR CITY: SAN FRANCISCO STATE: CA ZIP: 94104 SC 13D/A 1 AMENDMENT #1 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D (RULE 13D-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13D- 1(A) AND AMENDMENTS THERETO FILED PURSUANT TO 13D-2(A) (AMENDMENT NO. 1)/1/ MICROCIDE PHARMACEUTICALS, INC. ------------------------------- (Name of Issuer) Common Stock ------------ (Title of Class of Securities) 59501 8 102 ----------- (CUSIP Number) Hope Flack BVF Partners L.P. 333 West Wacker Drive, Suite 1600 Chicago, Illinois 60606 (312) 263-7777 -------------------------------------------- (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) October 15, 1997 ---------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b)(3) or (4), check the following box [_]. Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. (Continued on following pages) (Page 1 of 7 Pages) - ------------------------------- /1/ The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). - ----------------------- --------------------- CUSIP NO. 59501 8 102 13D PAGE 2 OF 7 PAGES - ----------------------- --------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSONS 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) BIOTECHNOLOGY VALUE FUND, L.P. - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) [X] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS* 4 WC - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) [_] 5 - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 DELAWARE - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 470,300 OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING 0 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 470,300 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 470,300 - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 4.3% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 14 PN - ------------------------------------------------------------------------------ *SEE INSTRUCTION BEFORE FILLING OUT! - ----------------------- --------------------- CUSIP NO. 59501 8 102 13D PAGE 3 OF 7 PAGES - ----------------------- --------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSONS 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) BVF Partners, L.P. - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) [X] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS* 4 OO - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 [_] - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 DELAWARE - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 886,300 OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING 0 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 886,300 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 886,300 - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 8.2% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 14 PN - ------------------------------------------------------------------------------ *SEE INSTRUCTION BEFORE FILLING OUT! - ----------------------- --------------------- CUSIP NO. 59501 8 102 13D PAGE 4 OF 7 PAGES - ----------------------- --------------------- - ------------------------------------------------------------------------------ NAME OF REPORTING PERSONS 1 I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) BVF INC. - ------------------------------------------------------------------------------ CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* 2 (a) [X] (b) [_] - ------------------------------------------------------------------------------ SEC USE ONLY 3 - ------------------------------------------------------------------------------ SOURCE OF FUNDS* 4 WC, OO - ------------------------------------------------------------------------------ CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) 5 [_] - ------------------------------------------------------------------------------ CITIZENSHIP OR PLACE OF ORGANIZATION 6 DELAWARE - ------------------------------------------------------------------------------ SOLE VOTING POWER 7 NUMBER OF 0 SHARES ----------------------------------------------------------- SHARED VOTING POWER BENEFICIALLY 8 886,300 OWNED BY ----------------------------------------------------------- EACH SOLE DISPOSITIVE POWER 9 REPORTING 0 PERSON ----------------------------------------------------------- SHARED DISPOSITIVE POWER WITH 10 886,300 - ------------------------------------------------------------------------------ AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 11 886,300 - ------------------------------------------------------------------------------ CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* 12 [_] - ------------------------------------------------------------------------------ PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 13 8.2% - ------------------------------------------------------------------------------ TYPE OF REPORTING PERSON* 14 IA,CO - ------------------------------------------------------------------------------ *SEE INSTRUCTION BEFORE FILLING OUT! - ----------------------- --------------------- CUSIP NO. 59501 8 102 13D PAGE 5 OF 7 PAGES - ----------------------- --------------------- Amendment No. 1 (the "Amendment") to the Statement on Schedule 13D, dated August 7, 1997 (the "Statement"), filed with the Securities and Exchange Commission on behalf of Biotechnology Value Fund, L.P., a Delaware limited partnership ("BVF"), BVF Partners L.P., a Delaware limited partnership ("Partners"), and BVF Inc., a Delaware corporation ("BVF Inc." and, together with BVF and Partners, the "Reporting Persons") with respect to the Common Stock, no par value (the "Stock"), of Microcide Pharmaceuticals, Inc., a Delaware corporation ("Microcide"). Item 3 is hereby amended to read in its entirety as follows: ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION. Since September 4, 1997, Partners, in its capacity as general partner of BVF, has purchased on behalf of such limited partnership an aggregate number of 161,100 shares of the Stock for an aggregate consideration of $1,923,420.22, utilizing funds provided by BVF from its working capital pursuant to the terms of its limited partnership agreement with Partners. In addition, Partners, in its capacity as investment manager with respect to certain managed accounts, has purchased on behalf of such managed accounts an aggregate number of 161,400 shares of the Stock for an aggregate consideration of $1,933,842.45, utilizing funds under management by Partners pursuant to investment management agreements between Partners and such managed accounts. Item 5 is hereby amended to read in its entirety as follows: ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. (a) BVF beneficially owns 470,300 shares of the Stock, Partners beneficially owns 886,300 shares of the Stock, and BVF Inc. beneficially owns 886,300 shares of the Stock, approximately 4.3%, 8.2% and 8.2%, respectively, of the aggregate number of shares outstanding as of July 31, 1997 (as reported in Microcide's quarterly statement on Form 10-Q for the quarter ending June 30, 1997). (b) BVF shares voting and dispositive power over the 470,300 shares of the Stock it beneficially owns with Partners. Partners and BVF Inc. share voting and dispositive power over the 886,300 shares of the Stock they beneficially own with, in addition to BVF, the managed accounts on whose behalf Partners, as investment manager, purchased such shares. The managed accounts on whose behalf Partners owns shares of the Stock are Investment 10 L.L.C., an Illinois limited liability company ("ILL10"), Palamundo, L.D.C., a limited duration company organized under the laws of the Cayman Islands ("Palamundo"), ZPG Securities, L.L.C., a New York limited liability company ("ZPG") and Biotechnology Value Fund, Ltd., a Cayman Islands Corporation ("BVF Ltd."). ILL10, Palamundo, ZPG and BVF Ltd. are collectively referred to herein as the "Accounts." The Accounts specialize in holding - ----------------------- --------------------- CUSIP NO. 59501 8 102 13D PAGE 6 OF 7 PAGES - ----------------------- --------------------- biotechnology stocks for investment purposes and the business address of each is BVF Partners L.P., 333 West Wacker Drive, Suite 1600, Chicago, Illinois 60606. (c) Exhibit B attached hereto contains information as to all transactions in the Stock by the Reporting Persons during the past sixty days. All such transactions were made for cash in open market, over-the-counter transactions. No other transactions in the Stock have been effected by the Reporting Persons during the past sixty days. (d) The Accounts are entitled to receive dividends and any sale proceeds with respect to the Stock in proportion to their respective ownership interests therein. Item 7 is hereby amended to read in its entirety as follows: ITEM 7. MATERIAL TO BE FILED AS EXHIBITS. Exhibit A - Agreement Regarding Joint Filing Exhibit B - Transactions in the Stock by the Reporting Persons during the last 60 days. - ----------------------- --------------------- CUSIP NO. 59501 8 102 13D PAGE 7 OF 7 PAGES - ----------------------- --------------------- After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: November 10, 1997. BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT ---------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT ---------------------------- Mark N. Lampert President BVF INC. By: /s/ MARK N. LAMPERT ------------------------------------- Mark N. Lampert President EX-99.A 2 AGREEMENT REGARDING JOINT FILING EXHIBIT A AGREEMENT REGARDING JOINT FILING -------------------------------- The undersigned, Biotechnology Value Fund, L.P., a Delaware limited partnership, and BVF Partners L.P., a Delaware limited partnership, and BVF Inc., a Delaware corporation, hereby agree and acknowledge that the Amendment containing the information required by Schedule 13D, to which this Agreement is attached as an exhibit, is filed on behalf of each of them. The undersigned further agree that any further amendments or supplements thereto shall also be filed on behalf of each of them. Dated: November 10, 1997. BIOTECHNOLOGY VALUE FUND, L.P. By: BVF Partners L.P., its general partner By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT ------------------------------------- Mark N. Lampert President BVF PARTNERS L.P. By: BVF Inc., its general partner By: /s/ MARK N. LAMPERT ----------------------------------------- Mark N. Lampert President BVF INC. By: /s/ MARK N. LAMPERT ------------------------------------- Mark N. Lampert President EX-99.B 3 STOCK TRANSACTIONS BY REPORTING PERSONS EXHIBIT B TRANSACTIONS IN THE STOCK BY THE REPORTING PERSONS -------------------------------------------------- DURING THE PAST SIXTY DAYS --------------------------
Settlement For the - ---------- By ------ Quantity Price per Type of Broker Date -- Account of -------- --------- ------- ------ ---- ----------- Share Trade - -------------------------------------------------------------------------------------- 09/04/97 Partners ZPG 2,400 $11.8750 Purchase INET - -------------------------------------------------------------------------------------- 09/08/97 Partners BVF 4,000 $12.7500 Purchase MLCO - -------------------------------------------------------------------------------------- 09/08/97 Partners ILL10 2,000 $12.7500 Purchase MLCO - -------------------------------------------------------------------------------------- 09/08/97 Partners BVF Ltd. 4,000 $12.7500 Purchase MLCO - -------------------------------------------------------------------------------------- 09/09/97 Partners BVF 12,000 $12.5000 Purchase MLCO - -------------------------------------------------------------------------------------- 09/09/97 Partners ILL10 5,000 $12.5000 Purchase MLCO - -------------------------------------------------------------------------------------- 09/09/97 Partners PAL 3,000 $12.5000 Purchase MLCO - -------------------------------------------------------------------------------------- 09/09/97 Partners ZPG 2,000 $12.5000 Purchase MLCO - -------------------------------------------------------------------------------------- 09/09/97 Partners BVF Ltd. 8,000 $12.5000 Purchase MLCO - -------------------------------------------------------------------------------------- 09/10/97 Partners BVF Ltd. 3,200 $12.2500 Purchase PFTC - -------------------------------------------------------------------------------------- 09/11/97 Partners BVF 13,000 $12.2500 Purchase MLCO - -------------------------------------------------------------------------------------- 09/11/97 Partners ILL10 3,000 $12.2500 Purchase MLCO - -------------------------------------------------------------------------------------- 09/11/97 Partners BVF Ltd. 9,000 $12.2500 Purchase MLCO - -------------------------------------------------------------------------------------- 09/12/97 Partners BVF 5,400 $12.1875 Purchase INET - -------------------------------------------------------------------------------------- 09/12/97 Partners BVF Ltd. 3,000 $12.1875 Purchase INET - -------------------------------------------------------------------------------------- 10/01/97 Partners BVF 6,400 $12.2773 Purchase INET - -------------------------------------------------------------------------------------- 10/02/97 Partners BVF 300 $12.3750 Purchase INET - -------------------------------------------------------------------------------------- 10/03/97 Partners BVF 5,000 $12.2500 Purchase COWN - -------------------------------------------------------------------------------------- 10/15/97 Partners BVF Ltd. 1,800 $12.1250 Purchase INET - -------------------------------------------------------------------------------------- 10/17/97 Partners BVF Ltd. 4,500 $12.2361 Purchase INET - -------------------------------------------------------------------------------------- 10/27/97 Partners BVF 25,000 $12.2500 Purchase COWN - -------------------------------------------------------------------------------------- 10/27/97 Partners PAL 5,000 $12.2500 Purchase COWN - -------------------------------------------------------------------------------------- 10/27/97 Partners BVF Ltd. 20,000 $12.2500 Purchase COWN - -------------------------------------------------------------------------------------- 10/27/97 Partners BVF Ltd. 4,500 $12.1250 Purchase PFTC - -------------------------------------------------------------------------------------- 10/29/97 Partners BVF 45,000 $12.0000 Purchase COWN - -------------------------------------------------------------------------------------- 10/29/97 Partners ILL10 4,000 $12.0000 Purchase COWN - -------------------------------------------------------------------------------------- 10/29/97 Partners PAL 5,000 $12.0000 Purchase COWN - --------------------------------------------------------------------------------------
Settlement For the - ---------- By ------ Quantity Price per Type of Broker Date -- Account of -------- --------- ------- ------ ---- ----------- Share Trade - -------------------------------------------------------------------------------------- 10/29/97 Partners ZPG 3,000 $12.0000 Purchase COWN - -------------------------------------------------------------------------------------- 10/29/97 Partners BVF Ltd. 43,000 $12.0000 Purchase COWN - -------------------------------------------------------------------------------------- 10/29/97 Partners BVF 15,000 $12.0625 Purchase MLCO - -------------------------------------------------------------------------------------- 10/30/97 Partners BVF 30,000 $10.8750 Purchase COWN - -------------------------------------------------------------------------------------- 10/30/97 Partners ILL10 4,000 $10.8750 Purchase COWN - -------------------------------------------------------------------------------------- 10/30/97 Partners PAL 2,500 $10.8750 Purchase COWN - -------------------------------------------------------------------------------------- 10/30/97 Partners ZPG 2,000 $10.8750 Purchase COWN - -------------------------------------------------------------------------------------- 10/30/97 Partners BVF Ltd. 17,500 $10.8750 Purchase COWN - --------------------------------------------------------------------------------------
MLCO Merrill Lynch & Co. INET Instinet COWN Cowen & Company PFTC Preferred Technologies SROS: COMPANY DATA COMPANY CONFORMED NAME: CENTRAL INDEX KEY: STANDARD INDUSTRIAL CLASSIFICATION: IRS NUMBER: STATE OF INCORPORATION: FISCAL YEAR END: BUSINESS ADDRESS STREET 1: STREET 2: CITY: STATE: ZIP: BUSINESS PHONE: FORMER COMPANY FORMER CONFORMED NAME: DATE OF NAME CHANGE: -----END PRIVACY-ENHANCED MESSAGE-----